These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 7881774)

  • 1. Extrapyramidal symptoms with selective serotonin reuptake inhibitors.
    Arya DK
    Br J Psychiatry; 1994 Dec; 165(6):728-33. PubMed ID: 7881774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin reuptake inhibitor-related extrapyramidal side effects in two patients with cerebral palsy.
    Rone LA; Ferrando SJ
    Psychosomatics; 1996; 37(2):165-6. PubMed ID: 8742546
    [No Abstract]   [Full Text] [Related]  

  • 3. [Neurobiology and pharmacotherapy of social phobia].
    Aouizerate B; Martin-Guehl C; Tignol J
    Encephale; 2004; 30(4):301-13. PubMed ID: 15538306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.
    Hedenmalm K; Güzey C; Dahl ML; Yue QY; Spigset O
    J Clin Psychopharmacol; 2006 Apr; 26(2):192-7. PubMed ID: 16633151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Diagnostic clinical Interview for Drug Withdrawal 1 (DID-W1) – New Symptoms of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI): inter-rater reliability.
    Cosci F; Chouinard G; Chouinard VA; Fava GA
    Riv Psichiatr; 2018; 53(2):95-99. PubMed ID: 29674777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review.
    Damsa C; Bumb A; Bianchi-Demicheli F; Vidailhet P; Sterck R; Andreoli A; Beyenburg S
    J Clin Psychiatry; 2004 Aug; 65(8):1064-8. PubMed ID: 15323590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrapyramidal symptoms associated with antidepressants--a review of the literature and an analysis of spontaneous reports.
    Madhusoodanan S; Alexeenko L; Sanders R; Brenner R
    Ann Clin Psychiatry; 2010 Aug; 22(3):148-56. PubMed ID: 20680187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of uptake for dopamine, but not norepinephrine or 5-HT, increases selection of high effort instrumental activity: Implications for treatment of effort-related motivational symptoms in psychopathology.
    Yohn SE; Errante EE; Rosenbloom-Snow A; Somerville M; Rowland M; Tokarski K; Zafar N; Correa M; Salamone JD
    Neuropharmacology; 2016 Oct; 109():270-280. PubMed ID: 27329556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    J Pharmacol Exp Ther; 2002 Dec; 303(3):952-8. PubMed ID: 12438514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects.
    Stahl SM
    J Affect Disord; 1998 Dec; 51(3):215-35. PubMed ID: 10333979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.
    Skop BP; Brown TM
    Psychosomatics; 1996; 37(1):12-6. PubMed ID: 8600488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective serotonin reuptake inhibitor-related extrapyramidal symptoms in autistic children: a case series.
    Sokolski KN; Chicz-Demet A; Demet EM
    J Child Adolesc Psychopharmacol; 2004; 14(1):143-7. PubMed ID: 15142402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors.
    Caley CF
    Ann Pharmacother; 1997 Dec; 31(12):1481-9. PubMed ID: 9416386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
    Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
    PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats.
    Kitaichi Y; Inoue T; Nakagawa S; Boku S; Kakuta A; Izumi T; Koyama T
    Eur J Pharmacol; 2010 Nov; 647(1-3):90-6. PubMed ID: 20816814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety.
    Blier P; Szabo ST
    J Clin Psychiatry; 2005; 66 Suppl 8():30-40. PubMed ID: 16336034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selective serotonin reuptake inhibitor(SSRI)].
    Motohashi N
    Nihon Rinsho; 2001 Aug; 59(8):1519-22. PubMed ID: 11519151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons.
    Guiard BP; Chenu F; El Mansari M; Blier P
    Int J Neuropsychopharmacol; 2011 Mar; 14(2):211-23. PubMed ID: 20149268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensory disturbances associated with serotonin reuptake inhibitors: brief review.
    Praharaj SK; Arora M; Sarkhel S
    Hum Psychopharmacol; 2010 Apr; 25(3):216-21. PubMed ID: 20373472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute extrapyramidal syndrome induced by escitalopram: a case report.
    Nimber JS; Aggarwal A
    Psychopharmacology (Berl); 2014 Sep; 231(18):3813-4. PubMed ID: 25048289
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.